MATINAS BIOPHARMA HOLDINGS I (MTNB) Fundamental Analysis & Valuation

NYSEARCA:MTNB • US5768103039

Current stock price

0.5501 USD
+0 (+0.2%)
At close:
0.5699 USD
+0.02 (+3.6%)
After Hours:

This MTNB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. MTNB Profitability Analysis

1.1 Basic Checks

  • MTNB had negative earnings in the past year.
  • MTNB had a negative operating cash flow in the past year.
  • MTNB had negative earnings in each of the past 5 years.
  • MTNB had a negative operating cash flow in each of the past 5 years.
MTNB Yearly Net Income VS EBIT VS OCF VS FCFMTNB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M

1.2 Ratios

  • With a Return On Assets value of -336.45%, MTNB is not doing good in the industry: 92.64% of the companies in the same industry are doing better.
  • With a Return On Equity value of -502.09%, MTNB is not doing good in the industry: 77.52% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -336.45%
ROE -502.09%
ROIC N/A
ROA(3y)-110.03%
ROA(5y)-80.29%
ROE(3y)-165.34%
ROE(5y)-115.52%
ROIC(3y)N/A
ROIC(5y)N/A
MTNB Yearly ROA, ROE, ROICMTNB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for MTNB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MTNB Yearly Profit, Operating, Gross MarginsMTNB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. MTNB Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, MTNB has more shares outstanding
  • MTNB has less shares outstanding than it did 5 years ago.
  • The debt/assets ratio for MTNB has been reduced compared to a year ago.
MTNB Yearly Shares OutstandingMTNB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
MTNB Yearly Total Debt VS Total AssetsMTNB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of -48.85, we must say that MTNB is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -48.85, MTNB is doing worse than 92.05% of the companies in the same industry.
  • A Debt/Equity ratio of 0.00 indicates that MTNB is not too dependend on debt financing.
  • MTNB has a Debt to Equity ratio (0.00) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -48.85
ROIC/WACCN/A
WACCN/A
MTNB Yearly LT Debt VS Equity VS FCFMTNB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M

2.3 Liquidity

  • A Current Ratio of 2.79 indicates that MTNB has no problem at all paying its short term obligations.
  • With a Current ratio value of 2.79, MTNB is not doing good in the industry: 65.50% of the companies in the same industry are doing better.
  • MTNB has a Quick Ratio of 2.79. This indicates that MTNB is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 2.79, MTNB is doing worse than 63.37% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.79
Quick Ratio 2.79
MTNB Yearly Current Assets VS Current LiabilitesMTNB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. MTNB Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 24.18% over the past year.
  • Looking at the last year, MTNB shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)24.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.64%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 57.54% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y63.31%
EPS Next 2Y-10.59%
EPS Next 3Y30.93%
EPS Next 5Y57.54%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MTNB Yearly Revenue VS EstimatesMTNB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2018 2019 2020 2021 2022 2023 2027 2028 2029 2030 2031 2032 200M 400M 600M
MTNB Yearly EPS VS EstimatesMTNB Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 20 40 60

More info and screens

Find the best growth stocksShow best growing peers

1

4. MTNB Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MTNB. In the last year negative earnings were reported.
  • Also next year MTNB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MTNB Price Earnings VS Forward Price EarningsMTNB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MTNB Per share dataMTNB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4 -5

4.3 Compensation for Growth

  • MTNB's earnings are expected to grow with 30.93% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.59%
EPS Next 3Y30.93%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MTNB Dividend Analysis

5.1 Amount

  • MTNB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MTNB Fundamentals: All Metrics, Ratios and Statistics

MATINAS BIOPHARMA HOLDINGS I

NYSEARCA:MTNB (4/21/2026, 8:04:00 PM)

After market: 0.5699 +0.02 (+3.6%)

0.5501

+0 (+0.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-31
Earnings (Next)05-13
Inst Owners7.06%
Inst Owner Change-0.09%
Ins Owners8.67%
Ins Owner Change0%
Market Cap3.53M
Revenue(TTM)N/A
Net Income(TTM)-24.25M
Analysts45.71
Price TargetN/A
Short Float %0.18%
Short Ratio0.37
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.73
P/tB 1.37
EV/EBITDA N/A
EPS(TTM)-4.17
EYN/A
EPS(NY)-5.1
Fwd EYN/A
FCF(TTM)-2.48
FCFYN/A
OCF(TTM)-2.48
OCFYN/A
SpS0
BVpS0.75
TBVpS0.4
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -336.45%
ROE -502.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-110.03%
ROA(5y)-80.29%
ROE(3y)-165.34%
ROE(5y)-115.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.79
Quick Ratio 2.79
Altman-Z -48.85
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.64%
EPS Next Y63.31%
EPS Next 2Y-10.59%
EPS Next 3Y30.93%
EPS Next 5Y57.54%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8.5%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-2.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.97%
OCF growth 3YN/A
OCF growth 5YN/A

MATINAS BIOPHARMA HOLDINGS I / MTNB Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for MATINAS BIOPHARMA HOLDINGS I?

ChartMill assigns a fundamental rating of 1 / 10 to MTNB.


Can you provide the valuation status for MATINAS BIOPHARMA HOLDINGS I?

ChartMill assigns a valuation rating of 1 / 10 to MATINAS BIOPHARMA HOLDINGS I (MTNB). This can be considered as Overvalued.


What is the profitability of MTNB stock?

MATINAS BIOPHARMA HOLDINGS I (MTNB) has a profitability rating of 0 / 10.


What is the expected EPS growth for MATINAS BIOPHARMA HOLDINGS I (MTNB) stock?

The Earnings per Share (EPS) of MATINAS BIOPHARMA HOLDINGS I (MTNB) is expected to grow by 63.31% in the next year.